- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02618733
Comparing Ticagrelor Versus Clopidogrel on Microcirculation (PLEIO)
A Prospective Randomized Controlled Clinical Trial of Comparing ticagreLor Versus clopidogrEl on mIcrocirculation in Patients With Acute cOronary Syndrome Study
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This study is a prospective, randomized, open-label, active controlled study with two parallel study groups.
For inclusion in the study subjects should fulfill the following criteria:
- Provision of informed consent prior to any study specific procedures
- Female or male aged 20-85 years
- All patients with ACS scheduled for PCI will be eligible, assuming their ability to understand the character and individual consequences of participation as well as giving written informed consent.
- Be able to understand and comply with the requirements of the study, as judged by the investigator.
To investigate the effects of ticagrelor on coronary microcirculation, IMR will be measured twice, 6 months apart in the same lesion, compared with clopidogrel.
The IMR is defined as simultaneously measured distal coronary pressure divided by the inverse of the thermodilution-derived hyperaemic mean transit time (Tmn), or more simply, distal coronary pressure multiplied by the Tmn.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Busan, Korea, Republikken
- Department of Internal Medicine,Dong-A University College of Medicine
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Provision of informed consent prior to any study specific procedures
- All patients with ACS scheduled for PCI will be eligible, assuming their ability to understand the character and individual consequences of participation as well as giving written informed consent.
- Be able to understand and comply with the requirements of the study, as judged by the investigator.
Exclusion Criteria:
- History of intracranial bleeding
- Severe hepatic impairment
- Active pathologic bleeding
- Hypersensitivity to ticagrelor or any of the excipients
- Liver cirrhosis greater than or equal to Child class B
- Decreased serum platelet level (≤ 100,000/uL)
- Life expectancy ≤ 1 year
- Need for chronic oral anticoagulant therapy
- Patients with known bleeding diathesis or coagulation disorder
- History of previous intracranial bleed at any time, gastrointestinal bleed within the past 6 months, or major surgery within 30 days.
- Ischemic stroke within the previous 14 days
- Renal failure requiring dialysis or anticipated need for dialysis during the course of the study
- Concern for inability of the patient to comply with study procedures and/or follow up
- Unable to give informed consent.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Ticagrelor
Ticagrelor 90mg, twice a day
|
90mg, twice a day
|
Aktiv komparator: Clopidogrel
Clopidogrel 75mg, once a day
|
75mg, once a day
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Index of microcirculatory resistance using 0.014-in coronary pressure wire
Tidsramme: 6 months
|
6 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Fractional flow reserve using 0.014-in coronary pressure wire
Tidsramme: 6 months
|
6 months
|
Coronary flow reserve using 0.014-in coronary pressure wire
Tidsramme: 6 months
|
6 months
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Kyungil Park, MD, Dong-A University
Publikationer og nyttige links
Generelle publikationer
- Moon H, Jo YS, Kim SJ, Jo S, Park K. Comparison of ticagrelor with clopidogrel on quality of life in patients with acute coronary syndrome. Health Qual Life Outcomes. 2021 Oct 16;19(1):242. doi: 10.1186/s12955-021-01875-w.
- Jeong YJ, Park K, Kim YD. Comparison between ticagrelor and clopidogrel on myocardial blood flow in patients with acute coronary syndrome, using 13 N-ammonia positron emission tomography. Am Heart J. 2020 Apr;222:121-130. doi: 10.1016/j.ahj.2020.01.013. Epub 2020 Jan 27.
- Park K, Cho YR, Park JS, Park TH, Kim MH, Kim YD. Comparison of the Effects of Ticagrelor and Clopidogrel on Microvascular Dysfunction in Patients With Acute Coronary Syndrome Using Invasive Physiologic Indices. Circ Cardiovasc Interv. 2019 Oct;12(10):e008105. doi: 10.1161/CIRCINTERVENTIONS.119.008105. Epub 2019 Sep 26.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Myokardieiskæmi
- Hjertesygdomme
- Hjerte-kar-sygdomme
- Karsygdomme
- Sygdom
- Syndrom
- Akut koronarsyndrom
- Lægemidlers fysiologiske virkninger
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Blodpladeaggregationshæmmere
- Purinerge P2Y-receptorantagonister
- Purinerge P2-receptorantagonister
- Purinerge antagonister
- Purinerge midler
- Ticagrelor
- Clopidogrel
Andre undersøgelses-id-numre
- 14-218
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Akut koronarsyndrom
-
IRCCS Policlinico S. DonatoRekrutteringAnomalous aorta origin of the coronary artery (AAOCA)Italien
-
Riphah International UniversityAfsluttet
-
Shaare Zedek Medical CenterUkendtPræmenstruelt syndrom - PMS
-
Riphah International UniversityAfsluttet
-
Esra ÖZERKTO Karatay UniversityRekrutteringEffekten af aromaterapiapplikation med bergamot og grapefrugt æteriske olier på PMS (Aromatherapy)Præmenstruelt syndrom - PMSKalkun
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.AfsluttetTidligere behandlet myelodysplastisk syndrom | Myelodysplastisk syndrom | Terapi-relateret myelodysplastisk syndrom | Sekundært myelodysplastisk syndrom | Refraktært højrisiko myelodysplastisk syndromForenede Stater
-
Hrain Biotechnology Co., Ltd.Shanghai Changzheng HospitalAktiv, ikke rekrutterendePOMES syndrom | Tilbagefaldende og refraktær POMES-syndromKina
-
Riphah International UniversityRekrutteringNedre kors syndromPakistan
-
Foundation University IslamabadRekruttering
-
University of CalgaryUkendtNefrotisk syndrom hos børn | Nefrotisk syndrom, minimal ændring | Nefrotisk syndrom, idiopatiskCanada
Kliniske forsøg med Ticagrelor
-
Federico II UniversityAdvicePharma GroupAfsluttetMyokardieinfarkt | Koronararteriesygdom | Akut koronarsyndrom | STEMI | NSTEMIItalien
-
Collegium Medicum w BydgoszczyAfsluttet
-
University of FloridaAfsluttet
-
AstraZenecaParexelAfsluttet
-
University of FloridaAstraZenecaAfsluttet
-
University of FloridaThe Medicines CompanyAfsluttetKoronararteriesygdomForenede Stater
-
David AntoniucciAstraZeneca; A.R. CARD Onlus FoundationAfsluttetAkut koronarsyndrom | Bivirkninger på antiblodplademiddelItalien, Grækenland
-
Centro Hospitalario La ConcepcionRekruttering
-
Sheba Medical CenterAfsluttetST Elevation Myokardieinfarkt | Akutte koronare syndromerIsrael
-
Cairo UniversityAfsluttetHjerte-kar-sygdomme | Akut koronarsyndromEgypten